Skip to main content
x

Recent articles

Safety remains the key metric for Cogent

Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.

Conjugates dominate human trial entries

ADCs newly into human trials include Lilly's PTK7 and two bispecifics.

Regeneron enters the T-cell engager arena

Lynozyfic could have an edge over rival BCMA-targeting bispecifics.

M&A analysis: signs of life emerge

Some big deals in the second quarter have raised hopes that takeouts are back.

Dizal's US first; now what?

Zegfrovy is approved in a best-case setting, but Dizal has no US presence.

FDA red and green lights: June 2025

Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.